Virax Biolabs Group Limited Ordinary Shares

VRAX XNAS

Market Cap

2.5M

Short interest (Jul 15)

3.1%

Net Short (Jul 27 ): -0.6%

Borrow Fee

472.75%

↓ 1.6%

Available Shares

60K

↑ 132.4%

Price Chart

Company Overview

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

Company Info

Exchange: NASDAQ
CIK: 0001885827
Asset Type: CS

Market Data

Market Cap: $2,542,391
Employees: 26
Status: Active

Short Interest

Current Borrow Fee 472.75%
Range: 472.75% - 559.00%
Available Shares 60K
Range: 45K - 60K

Recent Changes

Fee Change: ↑ 0.7%
Available Change: ↑ 57.1%

Quick Actions

View Dilution Chart
Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime